4 Results for "

LSD1 protein level

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "LSD1 protein level" in MCE Product Catalog:

Cat. No.: HY-179229
Research Areas:  

Cancer

LSD1-IN-47 is a highly efficient PROTAC degrader targeting LSD1 (IC50 = 43 nM). LSD1-IN-47 does not alter LSD1 protein levels and does not increase the histone marker H3K4me2. LSD1-IN-47 can be used for the study of colon carcinoma .
loading...
    loading...
Cat. No.: HY-123577
CAS No.: 2098621-17-9
Research Areas:  

Cancer

TPC-144 is a LSD1/KDM1A inhibitor. TPC-144 inhibits LSD1, and leads to a decrease in the protein level of DNMT1, causing low methylation of the LINE-1 element. TPC-144 can also produce a synergistic effect with Decitabine (HY-A0004) (a DNMT inhibitor), jointly promoting DNA demethylation and thereby inducing differentiation and apoptosis of leukemia cells. TPC-144 has also demonstrated anti-tumor efficacy in acute myeloid leukemia (AML) models. TPC-144 can be used for the study of AML .
loading...
    loading...
Cat. No.: HY-183202
CAS No.: 1456907-39-3
Research Areas:  

Cancer

NCD38 is a Lysine-specific demethylase 1 (LSD1) inhibitor with a target IC50 of 0.59 μM. NCD38 selectively disrupts LSD1-GFI1B interactions, dissociates LSD1 and CoREST from the ERG super-enhancer. NCD38 increases apoptosis-related protein levels, induces apoptosis and reduces SOX2 and Oct4 levels. NCD38 can be used for the research of acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-15313B
CAS No.: 2070014-96-7
Purity:  ≥98.0%
Target:  

Histone Demethylase

Research Areas:  

Metabolic Disease Cancer

CBB1007 hydrochloride is a reversible and selective LSD1 inhibitor with an IC50 of 5.27 µM for human LSD1. CBB1007 hydrochloride significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 hydrochloride shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 hydrochloride is studied in  non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma .
loading...
    loading...